Back to Search
Start Over
A Patient-Centered Mobile Intervention to Promote Self-Management and Improve Patient Outcomes in Chronic Heart Failure: The ManageHF Trial
- Source :
- Journal of Cardiac Failure. 25:S104
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Introduction Heart failure (HF) is the most common hospital discharge diagnosis among older adults. As a result, the management of HF is moving toward a proactive real-time technological model of assisting patients with monitoring and self-management. Hypothesis Our hypothesis was that a patient-centered mobile application, ManageHF, would reduce Minnesota Living with Heart Failure Questionnaire (MLHFQ) at 6 and 12 weeks post-hospital discharge compared to usual care. Methods A single-center randomized controlled trial was performed. Patients were included if they were greater than 45 years of age, had a left ventricular ejection fraction (LVEF) 40% (with LA size >40 mm or BNP > 200 pg/ml or NT-proBNP > 800 pg/ml) and were currently admitted or recently discharged for acute on chronic decompensated HF. Patients were excluded for any of the following: unstable coronary syndromes within 8 weeks, primary valvular heart disease, constrictive pericardial disease, uncorrected thyroid disease, dialysis or creatinine >4.0 mg/dL, a hospice candidate, active cancer, pulmonary fibrosis, discharged to a setting other than home, or required a chronic inotrope. The intervention group used a mobile application, ManageHF, along with a Fitbit wearable and scale. The mobile application prompted active self-monitoring and provided a health status indicator to promote self-management. The control group received usual care. The primary outcome was the change in MLHFQ from baseline to 6 and 12 weeks using mixed models. Secondary outcomes were the Self-Care Heart Failure Index (SCHFI) questionnaire and HF admissions. Results Eighty-two patients were enrolled and completed all baseline assessments. Baseline characteristics were similar between groups with the exception of HF type. The intervention group had a reduced MLHFQ at 6 weeks (p=0.026) but not at 12 weeks (p=0.61) compared to control (Figure). There was no effect of the intervention on the SCHFI or any of its subcomponents at 6 or 12 weeks. The time to first HF admission was not statistically different between the two groups (HR 0.85, 95% CI 0.36-2.0, p=0.71). Median number of days the intervention group performed self-monitoring was 63 days. Conclusion ManageHF improved MLHFQ at 6 weeks, but did not sustain its effects at 12 weeks. No effect was seen on self-care measured by SCHFI. Further research is needed to enhance engagement in the app for a longer period of time and to determine if the app can reduce HF admissions in a larger study.
- Subjects :
- Inotrope
medicine.medical_specialty
Creatinine
Self-management
Ejection fraction
business.industry
medicine.medical_treatment
valvular heart disease
030204 cardiovascular system & hematology
medicine.disease
law.invention
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
Randomized controlled trial
law
Internal medicine
Heart failure
Medicine
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
Dialysis
Subjects
Details
- ISSN :
- 10719164
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- Journal of Cardiac Failure
- Accession number :
- edsair.doi...........8c7def1f7bd896671ebb0e35bec89814
- Full Text :
- https://doi.org/10.1016/j.cardfail.2019.07.296